Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Zeen Tong"'
Autor:
Heather K. Raymon, Sabita Sankar, Peter Worland, Stacie S. Canan, Mehran F. Moghaddam, Brian E. Cathers, Zeen Tong, Wen Qing Yang, Tao Shi, Tam Tran, Sophie Perrin-Ninkovic, Sophie X. Peng, Samantha Richardson, Rene Bissonette, Rama Krishna Narla, Matt Hickman, Kamran Ghoreishi, Julius Apuy, Jingjing Zhao, Jim Leisten, James C. Gamez, Godrej Khambatta, Garrick Packard, Weiming Xu, Shuichan Xu, Kimberly E. Fultz, Deborah S. Mortensen
mTOR is a serine/threonine kinase that regulates cell growth, metabolism, proliferation, and survival. mTOR complex-1 (mTORC1) and mTOR complex-2 (mTORC2) are critical mediators of the PI3K–AKT pathway, which is frequently mutated in many cancers,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ce3c68a5bf01dbc4b5578e36679e558
https://doi.org/10.1158/1535-7163.c.6536589.v1
https://doi.org/10.1158/1535-7163.c.6536589.v1
Publikováno v:
Pharmaceutical development and technology. 27(4)
Formulating poorly water soluble, weakly basic drugs with consistent exposure is often a challenge due to pH-dependent solubility. When the oral formulation is exposed to different pH ranges in the gastrointestinal (GI) tract, drug precipitation, or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e887210c857ade3cbad2bc032ed83ca4
https://pubmed.ncbi.nlm.nih.gov/35502986
https://pubmed.ncbi.nlm.nih.gov/35502986
Autor:
Leon Carayannopoulos, Josephine Reyes, Xiaomin Wang, Yan Li, Simon Zhou, Yiming Cheng, Zeen Tong
Publikováno v:
Journal of clinical pharmacologyReferences. 62(4)
As a first-in-class, selective, potent inhibitor of the isocitrate dehydrogenase-2 (IDH2) mutant protein, enasidenib was approved by the US Food and Drug Administration in 2017 for the treatment of adult patients with relapsed or refractory acute mye
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19341653429c5b132c25eca396c2910c
https://pubmed.ncbi.nlm.nih.gov/34617279
https://pubmed.ncbi.nlm.nih.gov/34617279
Publikováno v:
Clinical Pharmacology: Advances and Applications. 11:39-50
Background Enasidenib (IDHIFA®, AG-221) is a first-in-class, targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. This was a Phase I/II study evaluating safety, efficacy, and pharmacokinetics/pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e49ed47315a0ebba9a868cd84c28c12
https://doi.org/10.2147/cpaa.s192687
https://doi.org/10.2147/cpaa.s192687
Autor:
Zeen Tong, Matthew Hoffmann, James D. Young, Sylvia Y.M. Yao, Usha Yerramilli, Sekhar Surapaneni
Publikováno v:
Xenobiotica. 49:1229-1236
1. The present study investigated inhibitory effects of enasidenib and its metabolite AGI-16903 on (a) recombinant human nucleoside transporters (hNTs) in hNT-producing Xenopus laevis oocytes, and ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca44bea0c974d331ccc39c25defea606
https://doi.org/10.1080/00498254.2018.1539783
https://doi.org/10.1080/00498254.2018.1539783
Autor:
Stephen E. Maxwell, Xiaomin Wang, Irene Nooijen, Wouter H. J. Vaes, Zeen Tong, Daniel Menezes, Esther van Duijn
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 202:114152
We report an accelerator mass spectrometry (AMS) assay to quantify azacitidine (Aza) incorporation into DNA and RNA from human acute myeloid leukemia (AML) cells, mouse bone marrow (BM) and peripheral blood mononuclear cells (PBMCs). Aza, a cytidine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76420f56baee521689b8c61f24436457
https://doi.org/10.1016/j.jpba.2021.114152
https://doi.org/10.1016/j.jpba.2021.114152
Publikováno v:
Clinical Pharmacology : Advances and Applications
Background Enasidenib (IDHIFA®, AG-221) is a first-in-class, targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. This was a Phase I/II study evaluating safety, efficacy, and pharmacokinetics/pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::671499524f160c002a7050f30c94ebf7
https://pubmed.ncbi.nlm.nih.gov/30858735
https://pubmed.ncbi.nlm.nih.gov/30858735
Autor:
Yan Li, Jim Nissel, Sekhar Surapaneni, Rangaraj Narayanan, Hong Liu, Christian Atsriku, Xiaomin Wang, Zeen Tong
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 49(1)
1. CC-223 was studied in vitro for metabolism and drug-drug interactions (DDI), and in clinic for interaction with ketoconazole. 2. In vitro, human metabolites of CC-223 included O-desmethyl CC-223 (M1), keto (M2), N-oxide (M3) and imine (M13), with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afef4248cd359e781f4071f3043cff4e
https://pubmed.ncbi.nlm.nih.gov/29297772
https://pubmed.ncbi.nlm.nih.gov/29297772
Autor:
Yan Li, Sekhar Surapaneni, Matthew Hoffmann, Josephine Reyes, Christian Atsriku, Usha Yerramilli, Bin Fan, Xiaomin Wang, Hua Yang, Zeen Tong
1. The absorption, distribution, metabolism and excretion (ADME) of enasidenib were studied following a single oral dose of [14C]enasidenib to rats (10 mg/kg; 100 μCi/kg) and healthy volunteers (100 mg; 318 nCi). 2. Enasidenib was readily absorbed,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a1e1dd43d337df221f77456b272741a
Autor:
Zeen Tong, Raushan T. Kurmasheva, Jianrong Wu, Terence M. Williams, E. Anders Kolb, Michael Arnold, Malcolm A. Smith, Moumita Chatterjee, Richard Gorlick, Peter J. Houghton, John M. Maris
Publikováno v:
Pediatric Blood & Cancer. 62:1214-1221
Background Nanoparticle albumin-bound paclitaxel (nab-paclitaxel, Abraxane®) is FDA approved for the treatment of several adult cancers. Antimitotic agents are essential components for curative therapy of pediatric solid tumors, although taxanes hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10f69312ab39f5dfd0d08f34687efbf8
https://doi.org/10.1002/pbc.25474
https://doi.org/10.1002/pbc.25474